Climb Bio (NASDAQ:CLYM – Get Free Report) was upgraded by equities researchers at Mizuho to a “strong-buy” rating in a note issued to investors on Monday, Zacks reports.
A number of other equities analysts have also weighed in on the stock. B. Riley Financial reiterated a “buy” rating and issued a $30.00 price target (up from $26.00) on shares of Climb Bio in a research report on Friday, September 4th. HC Wainwright increased their target price on Climb Bio from $24.00 to $30.00 and gave the stock a “buy” rating in a research report on Tuesday. Royal Bank Of Canada began coverage on shares of Climb Bio in a research note on Monday, August 3rd. They issued an “outperform” rating and a $23.00 price target on the stock. Oppenheimer raised their target price on shares of Climb Bio from $18.00 to $25.00 and gave the company an “outperform” rating in a report on Tuesday. Finally, Robert W. Baird lifted their price objective on shares of Climb Bio from $21.00 to $25.00 and gave the stock an “outperform” rating in a research note on Thursday, September 3rd. Two research analysts have rated the stock with a Strong Buy rating, thirteen have given a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Buy” and an average price target of $26.92.
View Our Latest Stock Report on CLYM
Climb Bio Stock Performance
Climb Bio (NASDAQ:CLYM – Get Free Report) last released its earnings results on Thursday, August 6th. The company reported ($0.18) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.21) by $0.03. Equities analysts forecast that Climb Bio will post -0.78 earnings per share for the current fiscal year.
Hedge Funds Weigh In On Climb Bio
Several large investors have recently modified their holdings of CLYM. Braidwell LP raised its holdings in Climb Bio by 102.6% during the 2nd quarter. Braidwell LP now owns 3,099,027 shares of the company’s stock valued at $40,411,000 after buying an additional 1,569,352 shares during the period. MPM Bioimpact LLC purchased a new position in Climb Bio during the fourth quarter worth $10,686,000. BlackRock Inc. bought a new position in Climb Bio during the second quarter valued at $30,708,000. Price T Rowe Associates Inc. MD increased its position in Climb Bio by 265.1% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 1,923,639 shares of the company’s stock valued at $7,695,000 after acquiring an additional 1,396,722 shares during the last quarter. Finally, ADAR1 Capital Management LLC raised its stake in shares of Climb Bio by 972.8% in the fourth quarter. ADAR1 Capital Management LLC now owns 1,432,475 shares of the company’s stock valued at $5,730,000 after acquiring an additional 1,298,945 shares during the period. Institutional investors own 69.76% of the company’s stock.
About Climb Bio
Climb Bio Therapeutics, Inc is a clinical-stage biotechnology company focused on the discovery and development of engineered protein therapeutics for the treatment of cancer and immune-mediated disorders. The company’s mission centers on designing biologics with enhanced specificity and functional activity to engage key cellular targets and improve patient outcomes in areas of high unmet need.
At the heart of Climb Bio’s approach is its proprietary protein engineering platform, which combines mammalian cell display, directed evolution and computational modeling.
Recommended Stories
- Five stocks we like better than Climb Bio
- Tesla’s Robotaxi Launch Wasn’t the Moment Investors Expected
- Despite Post-Earnings Drop, Wall Street Analysts Eye New Highs for Broadcom Stock
- Morgan Stanley Eyes Good Things Ahead for Meta After $18 Billion Legal Settlement
- Q3 Earnings Could Be the Catalyst the Market Has Been Waiting For
Receive News & Ratings for Climb Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Climb Bio and related companies with MarketBeat.com's FREE daily email newsletter.
